2009
Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840.
Rimm D, Broadwater G, Friedman P, Berry D, Seidman A, Hudis C, Winer E, Harris L, Thor A. Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. Cancer Research 2009, 69: 6046. DOI: 10.1158/0008-5472.sabcs-6046.Peer-Reviewed Original ResearchPrediction of responseHER2 expressionCooperative group clinical trialsPositive HER2 expressionGroup clinical trialReceiver operator characteristic curveOperator characteristic curveSubset of casesArea of expressionHeterogeneity of expressionHER2 stainingTH armNeoadjuvant settingStable diseaseProgressive diseaseRECIST criteriaPartial responseClinical outcomesCAP guidelinesPatient selectionPercentage of tissueT therapyClinical trialsHER2 testsLarge cohort
2005
Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342
Harris L, Perou C, Szallasi Z, Eklund A, Carter S, You F, Broadwater G, Monovich L, Winer E, Erlander M, Ellis M. Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342. Journal Of Clinical Oncology 2005, 23: 545-545. DOI: 10.1200/jco.2005.23.16_suppl.545.Peer-Reviewed Original Research